Professional paper

https://doi.org/10.15836/ccar2019.146

Krka’s Added-value Generic Medications

Mateja Grošelj orcid.org/0000-0002-4035-7691 ; Krka, d. d., Novo mesto, Slovenia
Breda Barbič-Žagar orcid.org/0000-0002-1173-7361 ; Krka, d. d., Novo mesto, Slovenia

Abstract

In its 65-year history, Krka has grown from a small pharmaceutical laboratory to become one of the leading generic pharmaceutical companies in the world. Krka’s innovative, added-value generic medications are developed using the company’s own know-how. This ensures that they hold certain key advantages over competitor products, resulting from the development of new technologies used in the production of active ingredients and dosage forms. When planning our product portfolio, we closely monitor the most common diseases in the modern world. We allow doctors and patients to choose from a wide variety of packaging, strengths, and single-pill combinations. The therapeutic equivalence of our medications with the originator’s medications is demonstrated by in vivo bioequivalence studies. The results of numerous clinical studies show that our medications are effective and well-tolerated by patients in clinical practice.

Keywords

added-value generics; quality; vertically integrated production; clinical studies

Hrčak ID:

221454

URI

https://hrcak.srce.hr/221454

Publication date:

26.6.2019.

Article data in other languages: croatian

Visits: 2.203 *